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Effectors of Th1 and Th17 cells act on
astrocytes and augment their
neuroinflammatory properties
Chittappen K. Prajeeth1, Julius Kronisch1, Reza Khorooshi2, Benjamin Knier7, Henrik Toft-Hansen3,4, Viktoria Gudi1,
Stefan Floess5, Jochen Huehn5, Trevor Owens2, Thomas Korn7,8 and Martin Stangel1,6*
Abstract
Background: Autoreactive Th1 and Th17 cells are believed to mediate the pathology of multiple sclerosis in the
central nervous system (CNS). Their interaction with microglia and astrocytes in the CNS is crucial for the regulation
of the neuroinflammation. Previously, we have shown that only Th1 but not Th17 effectors activate microglia.
However, it is not clear which cells are targets of Th17 effectors in the CNS.
Methods: To understand the effects driven by Th17 cells in the CNS, we induced experimental autoimmune
encephalomyelitis in wild-type mice and CD4+ T cell-specific integrin α4-deficient mice where trafficking of Th1
cells into the CNS was affected. We compared microglial and astrocyte response in the brain and spinal cord of
these mice. We further treated astrocytes with supernatants from highly pure Th1 and Th17 cultures and assessed
the messenger RNA expression of neurotrophic factors, cytokines and chemokines, using real-time PCR. Data
obtained was analyzed using the Kruskal-Wallis test.
Results: We observed in α4-deficient mice weak microglial activation but comparable astrogliosis to that of wild-
type mice in the regions of the brain populated with Th17 infiltrates, suggesting that Th17 cells target astrocytes
and not microglia. In vitro, in response to supernatants from Th1 and Th17 cultures, astrocytes showed altered
expression of neurotrophic factors, pro-inflammatory cytokines and chemokines. Furthermore, increased expression
of chemokines in Th1- and Th17-treated astrocytes enhanced recruitment of microglia and transendothelial
migration of Th17 cells in vitro.
Conclusion: Our results demonstrate the delicate interaction between T cell subsets and glial cells and how they
communicate to mediate their effects. Effectors of Th1 act on both microglia and astrocytes whereas Th17 effectors
preferentially target astrocytes to promote neuroinflammation.
Keywords: Astrocytes, Th1, Th17
Background
Inflammation of the central nervous system (CNS) dur-
ing multiple sclerosis (MS) or the animal model experi-
mental autoimmune encephalomyelitis (EAE) is believed
to be mediated by autoreactive T cells that are primed in
the periphery and infiltrate into the CNS through the
blood-brain barrier (BBB) [1, 2]. Among T cells,
predominantly, IFN-γ-producing Th1 cells and IL-17-
producing Th17 cells are key players in the pathogenesis
of MS and EAE [3, 4]. Much of our understanding has
been obtained from adoptive transfer experiments in ro-
dent EAE models, which suggest that both Th1 and
Th17 cells can mediate the disease in the CNS albeit
with a varying degree of severity [5–8]. Due to the com-
plexity of the neuroinflammatory process, there is only
little knowledge available on the individual contribution
of pathogenic Th1 and Th17 cells in regulating glial cell
function in the CNS.
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Of the CNS-resident cells, microglia and astrocytes are
known to play a central role in regulating the neuroin-
flammatory process [9–12]. Infiltrating effector T cells
are in constant crosstalk with resident glial cells, and re-
cently, we have demonstrated that effector molecules se-
creted by Th1 cells but not Th17 cells influence the
phenotype and function of microglia [13]. This was ra-
ther puzzling, considering the fact that Th17 cells are
highly pathogenic and microglia are highly immunoreac-
tive cell types in the CNS.
Only little is known about the crosstalk between T
cells and astrocytes, the major glial cell type of the brain.
Previously, astrocytes were considered to be involved in
the structural framework of neural tissue while their im-
munoreactive properties have been underestimated. Fur-
thermore, their intimate association with the BBB makes
them one of the first glial types to encounter cells infil-
trating into the CNS [14]. Subsequently, astrocyte activa-
tion regulates microglial recruitment and leukocyte
trafficking in the CNS during neuroinflammatory condi-
tions [15, 16]. In the past two decades, the contribution
of astrocytes to pro- and anti-inflammatory processes in
the CNS has gained prominence [17–20]. The import-
ance of astrocytes in regulating CNS inflammation has
been demonstrated by several studies which employed
strategies such as ablation of reactive astrocytosis or
blocking of selected receptor signaling specifically on as-
trocytes [10, 12, 21–23]. Upon activation, astrocytes up-
regulate major histocompatibility class (MHC)-I, MHC-
II and co-stimulatory molecules on their surface, which
highlights their ability to interact and present antigens
to T cells [24–26]. Nevertheless, there is only limited
knowledge about how the effector molecules released by
inflammatory Th1 and Th17 cells regulate the function
of astrocytes. In this study, we identified astrocytes as
targets of Th17 cells in the CNS and studied the ability
of effector molecules released by Th1 and Th17 cells to
influence their phenotype and function.
Methods
Mice
C57BL/6 mice were obtained from Charles River (Sulz-
feld, Germany) and housed under specific pathogen-free
conditions in the central animal facility of Hannover
Medical School (MHH), Germany. α4flox/flox has been
described previously [27]. CD4 Cre mice were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA).
CD4+ T cell-conditional α4 integrin-deficient (α4−/−)
mice were generated by crossing α4flox/flox mice with
CD4 Cre mice [28]. For EAE experiments, we obtained
glial fibrillary acidic protein (GFAP) HSV-thymidine kin-
ase (TK) mice on C57BL/6 background from The Jack-
son Laboratory (Bar Harbor, ME, USA) and the control
wild-type C57BL/6 mice in this case were from Taconic
(Taconic Europe, Ejby, Denmark). Animal experiments
were performed according to international guidelines on
the use of laboratory animals [29].
Experimental autoimmune encephalomyelitis
EAE was induced in GFAP HSV-TK mice, α4−/− mice, and
control B6 mice by immunization with MOG35–55 peptide
in complete Freund’s adjuvant, as described previously
[12, 28]. Mice were immunized at two subcutaneous sites
and received a total of 100 μg peptide and 200 or 250 μg
adjuvant. Additionally, 15 ng/g or 200 ng pertussis toxin
was administered i.p. on days 0 and 2. GFAP HSV-TK and
respective controls mice were scored on a 6-point scale as
follows: 0, no symptoms; 0.5, partial loss of tail tonus; 1,
complete loss of tail tonus; 2, difficulty to right, 3, paresis
in one or both hind legs; 4, paralysis in one or both hind
legs; 5, front limb paresis; and 6, moribund. All mice used
in the experiments were sacrificed 7 days after the onset
of clinical symptoms. Ataxic EAE in α4−/− mice was
scored, by four clinical subtests and categories of ledge
walking, hindlimb clasp, gait ataxia, and kyphosis with a
maximum of 3 points in each category, resulting in a po-
tential maximum score of 12 points [30]. Clinical signs of
classical EAE in respective wild-type controls mice were
assessed as reported [31].
Antibodies and reagents
Antibodies specific for mouse, anti-CD4 PerCP Cy5.5
(clone: RM 4.5), anti-CD8 APC (clone 53.6.7), anti-
CD11c APC (clone: N418), anti-IFN-γ APC (clone:
XMG1.2), anti-CD62L APC eFluor 780 (clone: MEL-14),
anti-F4/80 APC (clone: BM8), anti-CD3 (unconjugated,
clone: 145-2C11), anti-CD28 (unconjugated, clone:
37.51), and fixable viability dye eFluor 506 were pur-
chased from eBioscience (Frankfurt, Germany). Anti-
bodies to anti-CD25 APC (clone: PC61), anti-IL-17A
Pacific Blue (clone: TC11-18H10.1), anti-CD11b PE
(clone: M1/70), anti-B220 APC (clone RA3-6B2), and
anti-IL-10 FITC (JES5-16E3) were purchased from Bio-
Legend (San Diego, CA, USA). Unconjugated, anti-IFN-
γ (clone: XMG1.2), and anti-IL-4 (clone: 11B11) and
anti-IL-2 (clone JES6-1A12) were obtained from Bio X
Cell (NH, USA). Recombinant murine IL-6, IL-1β, gran-
ulocyte macrophage colony-stimulating factor (GM-
CSF), and porcine TGF-β1 were purchased from R&D
Systems (Wiesbaden-Nordenstadt, Germany) whereas
recombinant murine IFN-γ, TNF-α, and IL-12p70 were
from PeproTech (Hamburg, Germany). Recombinant
murine IL-17A was obtained from BioLegend (San
Diego, CA, USA).
In vitro differentiation of Th1 and Th17 cells
Naïve CD4+CD25− cells were differentiated in vitro into
Th1 and Th17 cells as previously described [13] with
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slight modifications. Briefly, after enrichment of CD4+ T
cells from the spleen and lymph nodes of C57BL/6 mice
using CD4+ T cell enrichment kit (BD Biosciences),
naïve CD4+CD62LhiCD25− cells were sort purified using
MoFlo (Beckman Coulter) or FACSAria (BD Biosci-
ences). Cells (5.0 × 105/ml) were stimulated with plate-
bound anti-CD3 (2 μg/ml) and anti-CD28 (2 μg/ml) in
12-well plates (Corning Life Science, Acton, MA, USA)
in complete Iscove’s Modified Dulbecco’s Medium
(IMDM, 10% FCS, 1 mM sodium pyruvate, 50 μM β-
mercaptoethanol, 25 mM HEPES, and non-essential
amino acids) supplemented with either Th1-polarizing
factors IL-12 (20 ng/ml) and anti-IL-4 (10 μg/ml) or
with Th17-polarizing factors TGF-β1 (2 ng/ml), IL-6
(30 ng/ml), TNF-α (20 ng/ml), IL-1β (10 ng/ml), anti-IL-
2 (10 μg/ml), and anti-IFN-γ (10 μg/ml). After 6 days of
culture, Th1 and Th17 cells were harvested and restimu-
lated in 12-well plates coated with anti-CD3 and anti-
CD28 antibodies for 6 h. Supernatants devoid of cells
were collected and stored at − 80 °C until further use.
Primary mouse mixed glial cultures
Primary cultures of mixed glial cells were prepared from
brains of postnatal 1–3-day-old C57BL/6 mice as de-
scribed [13]. Briefly, the brains were freed from menin-
ges and digested enzymatically with 0.1% trypsin (Sigma-
Aldrich) and 0.25% DNase (Roche, Mannheim,
Germany). Single cell suspensions obtained from the
digested brains were seeded into poly-L-lysine-coated T-
75-mm2 culture flasks in complete DMEM (DMEM + L-
glutamine + 4.5 g/L D-glucose; Gibco®, Darmstadt,
Germany) supplemented with 10% fetal calf serum
(FCS), 50 U/ml penicillin, and 50 μg/ml streptomycin
(all from Biochrom AG, Berlin, Germany). Microglia
were harvested from the confluent cultures by shaking
the culture flasks at 37 °C for 40 min at 180 rpm in an
orbital shaker. Remaining microglia and proliferating
oligodendrocyte precursor cells were eliminated by over-
night shaking at 37 °C and 170 rpm in an orbital shaker,
followed by cytosine arabinoside (AraC; 100 μM; Sigma-
Aldrich) treatment for 3 days. Astrocytes were harvested
from the culture flasks by mild trypsinization and were
replated into six-well plates at a density of 3 × 105 cells
per well. Confluent astrocyte cultures were shaken at
37 °C and 180 rpm in an orbital shaker for 4 h to elimin-
ate any remaining contaminating microglia. Astrocytes
obtained in this way were referred to as highly enriched
as they only had < 3% of microglial contamination
(CD11b+ cells).
Stimulation of astrocytes with Th1- and Th17-derived su-
pernatants and recombinant cytokines
Confluent astrocyte cultures as obtained in the above pro-
cedure were treated for 16 h with Th1- or Th17-derived
culture supernatants diluted with an equal volume of
complete DMEM. In all experiments, medium controls
refer to T cell culture medium (complete IMDM) col-
lected, frozen, and diluted with an equal volume of
complete DMEM just before the treatment of astrocytes.
In some experiments, astrocytes were treated for 16 h
with recombinant murine IFN-γ (50 ng/ml), TNF-α
(10 ng/ml), GM-CSF (5 ng/ml), and IL-17A (50 ng/ml) ei-
ther individually or in combination with others.
Reverse transcription polymerase chain reaction
RNA was isolated from the cell pellet using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s in-
structions. Equal amounts of RNA (750–1000 ng) were
subsequently transcribed into complementary DNA
(cDNA) with the High-Capacity cDNA Reverse Tran-
scription Kit (No. 4368814; Applied Biosystems®; Life
Technologies GmbH, Darmstadt, Germany). For gene
expression analysis, quantitative real-time PCR was per-
formed using the StepOne™ Real-Time PCR System and
appropriate TaqMan probes (Applied Biosystems, see
Additional file 1). The ΔΔCt method was applied to de-
termine differences in the expression between astrocytes
treated with medium and Th1 and Th17 supernatants.
For determination of expression of retinoic acid orphan
receptor c (Rorc) messenger RNA (mRNA) from the
spinal cord, 1 μg of RNA was used for cDNA synthesis.
Changes in mRNA expression levels were calculated
after normalization to hypoxanthine phosphoribosyl-
transferase (Hprt1) and glyceraldehyde 3-phosphate de-
hydrogenase (Gapdh).
ELISA
Supernatants of astrocytes cultured in the medium and
Th1 and Th17 supernatants, respectively, were collected
and stored at − 80 °C until further use. MCP-1/C-C che-
mokine ligand 2 (CCL2) (R&D Systems), CCL20 (R&D
Systems), and IL-6 (Thermo Fisher Scientific) were mea-
sured in the culture supernatants using enzyme-linked im-
munosorbent assay (ELISA) kits for mouse and carried
out according to the manufacturer’s instructions. A stand-
ard curve was generated as instructed using the standards
provided in the kit. The standard curve was calculated by
a computer-generated four-parameter log (4-PL) fit curve.
Histology
Animals were sacrificed at the peak of the disease and
perfused with cold PBS followed by 4% paraformalde-
hyde fixation (pH 7.4). The brain and spinal cord were
prepared separately, embedded in Tissue-Tek (Sakura),
and cryopreserved in liquid nitrogen. Twelve-
micrometer-thick coronal cortical brain, sagittal brain-
stem, and transverse lumbar spinal cord sections were
prepared using a cryotome. For immunofluorescence,
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sections were thawed and air-dried and, following 5-min
rehydration with PBS, were stained with primary rabbit
polyclonal anti-GFAP (Dako) or polyclonal rabbit Iba1
(Wako) antibodies in 0.1% Triton PBS for 2 h at room
temperature (RT). After thorough washing, sections
were incubated with Alexa Fluor 488- and Alexa Fluor
555-conjugated goat-anti-rabbit secondary antibodies,
respectively, in 0.1% Triton PBS for 1 h at RT. After
washing, slides were mounted with DAPI in Mowiol. Im-
ages were taken using a microscope (Olympus BX41)
with camera.
Transmigration of microglia
Astrocytes at 5 × 104 cells per well were plated into the
lower chamber of 24-well Transwell plates and cultured
until they reached confluence. Confluent astrocyte cul-
tures were treated with medium and Th1 and Th17 su-
pernatants (diluted with an equal volume of DMEM 10%
FCS) for 12 h. Following this, the cultures were washed
to remove the stimuli; fresh complete DMEM was added
and incubated for additional 4 h. Microglia harvested
after shaking the mixed glial cultures were added to the
Transwell inserts (8.0 μm pore, 24-well format; Costar®,
Corning, NY, USA) at 7 × 104 cells per insert, and the
inserts were placed into the chambers containing astro-
cytes. After 2 h of incubation at 37 °C, microglia on the
upper side of the insert were removed by using a cotton
swab. The filters were then fixed with 4% PFA, stained
with DAPI (1:2000), and mounted onto a glass slide with
Mowiol. The number of cells that had transmigrated to
the lower side of the membrane was counted (ten ran-
dom fields/filter) at × 20 magnification using an Olym-
pus BX41 fluorescence microscope.
Transendothelial migration of T cells
Primary C57BL/6 brain microvascular endothelial cells
(BMECs) and reagents needed for culturing them were
purchased from Cell Biologics (Chicago, USA). Cells
used for these experiments were from passages P5–P9.
Astrocytes at 3 × 105 cells per well were cultured in six-
well plates in complete DMEM until they reached con-
fluence. In parallel, BMECs (2.5 × 105 cells per insert)
were cultured on Transwell inserts (3.0 μm pore, poly-
carbonate membrane, six-well format; Costar®, Corning,
NY, USA) coated with gelatin-based coating solution
until they formed a confluent monolayer. Astrocytes
were treated with medium and Th1- and Th17-derived
supernatants (diluted in equal volumes of complete
DMEM) for 12 h and then washed thoroughly to remove
the T cell supernatants. Inserts with BMEC monolayers
were transferred to the chamber containing astrocytes
and co-cultured for an additional period of 4 h. To study
T cell migration, a total of 2 × 105 Th1 and Th17 cells
that were restimulated on anti-CD3/anti-CD28-coated
plates for 6 h were added on top of the BMEC mono-
layers. After 12 h, inserts were removed; culture medium
in the lower chamber containing transmigrated T cell
was collected, stained with anti-mouse CD4 PerCP
Cy5.5, and analyzed on FACSCalibur (BD Biosciences).
Each sample was acquired completely, and the cell
counts in the CD4+ gate were used to assess the transen-
dothelial migration of T cells.
Phagocytosis assay
Uptake of latex beads by microglia was measured as de-
scribed [32] with slight modifications. Briefly, 7.5 × 104
microglia were seeded on to astrocytes that were previ-
ously treated with medium and Th1- and Th17-derived
supernatants. Th1- and Th17-derived supernatants were
washed off before adding microglia. After 12 h of co-
culture with astrocytes, 107 Fluoresbrite™ YG carboxylate
microspheres (1 μm; Polysciences, Warrington, USA)
were added to the cells and incubated at 37 °C for 1 h. In
parallel, cells were also incubated with beads on ice and
this served as negative (4 °C) control. After thoroughly
washing away non-phagocytosed beads with ice-cold PBS,
cells were harvested and stained with anti-mouse CD11b
APC (M1-70), and phagocytosis was measured on a flow
cytometer (FACSCalibur; BD Biosciences). Shift in mean
fluorescence intensity (MFI) resulting from uptake of
fluorescent beads was used as a measure to assess phago-
cytosis. Active phagocytosis was calculated by subtracting
the MFI measured in 4 °C controls from the MFI mea-
sured in samples incubated at 37 °C.
Statistical analysis
All statistical analyses were conducted using GraphPad
Prism 5.0 (GraphPad Software). All data are expressed
as group mean ± SEM. All experiments were performed
multiple times (n ≥ 4), and the data obtained was ana-
lyzed using the Kruskal-Wallis test unless otherwise
stated. For analyzing EAE data, we used the Mann-
Whitney test. Results were considered statistically sig-
nificant at p < 0.05.
Results
Blockade of Th1 infiltration into the CNS during EAE
impairs astrogliosis in the spinal cord but not in the brain
Previously, we have demonstrated that only effector mol-
ecules secreted by Th1 cells but not Th17 cells activate
microglia [13]. Therefore, our aim was to identify the
targets of Th17 effectors during neuroinflammation in
the CNS. To address this, we employed a strategy of
blocking Th1 infiltration into the CNS and studied the
glial reaction in mice subjected to EAE. In an earlier
study, Rothhammer et al. [28] demonstrated that block-
ade or deletion of integrin α4β1 (VLA-4) on CD4+ T
lymphocytes preferentially inhibited the migration of Th1
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cells into the CNS during EAE. Interestingly, blockade of
Th1 migration into the CNS did not prevent the mice
from developing atypical EAE, a characteristic of Th17-
driven pathology (see Additional file 2), suggesting that
Th17 infiltration into the CNS under these conditions was
unaffected [28]. Therefore, we compared glial fibrillary
acidic protein (GFAP) expression (highly expressed in re-
active astrocytes) in the CNS of wild-type (WT) and T
cell-conditional α4-deficient (α4−/−) mice subjected to
EAE. GFAP staining was striking in the gray and white
matter of the lumbar spinal cord of WT mice, whereas the
GFAP expression was more restricted to white matter and
less evident in the gray matter of α4−/− mice (Fig. 1a–d).
This is most likely due to the fact that Th17 infiltration
into the spinal cord is reduced in the α4−/− mice as re-
ported in the previous study [28]. During EAE in α4−/−
mice, cellular infiltrates were found to be localized in the
brainstem, cerebellum, and cerebrum [28]. Analysis of the
cerebellum of WTand α4−/− mice showed a similar degree
of GFAP+ astrocytes in WT as well as α4−/− mice (Fig. 1e,
f ). This observation allows us to assume that in the ab-
sence of Th1 cells, effectors of Th17 are equally potent to
induce astrogliosis in the brain.
Microglia are morphologically different in EAE-induced
WT compared to α4−/− mice
We analyzed microglia in the brain and lumbar spinal
cord of WTand α4−/− mice subjected to EAE by immuno-
histochemistry. Iba1 staining revealed a higher number
and morphologically distinct Iba1+ microglia both in the
brain and spinal cord of WT mice compared to α4−/−
mice. Microglia detected in the spinal cord (Fig. 2) and
cerebellum of WT mice exhibited a hypertrophic pheno-
type with shorter and thicker processes, reminiscent of
highly activated microglia. In contrast, Iba1+ microglia in
α4−/− mice had a more bipolar structure with fewer and
finer process (Fig. 2). This is in accordance with our previ-
ous findings where we showed Th17 effectors do not have
direct influence on microglia [13]. Taken together, these
observations suggest that Th17 effectors are highly cap-
able of inducing astrocyte activation but less efficient in
driving microglial activation in the brain.
Th1- but not Th17-derived factors downregulate the ex-
pression of growth factors in astrocytes
Having understood that astrocytes are influenced by
Th17 cells, we further tested if Th1 and Th17 effectors
can have direct effects on astrocytes. In our previous
study, we have reported an efficient method to obtain
highly pure Th1 and Th17 cells in vitro and also charac-
terized their cytokine secretion profile [13]. The Th1
cells obtained by this method were devoid of Th17 cells
and vice versa. Cytokine profiling of Th1 and Th17 cell
culture supernatants revealed that Th1 cells
predominantly secreted IFN-γ and GM-CSF, whereas the
Th17 cells released large amounts of IL-17A and IL-17F
[13]. For determining the response of astrocytes to Th1-
and Th17-derived factors, we employed reverse tran-
scription polymerase chain reaction (RT-PCR) analysis
of RNA isolated from astrocytes that were treated with
medium and Th1- and Th17-derived supernatants. As-
trocytes are an important source of neurotrophic factors
needed for the maintenance of neural tissue. Factors re-
leased by cells infiltrating from the periphery during
neuroinflammation can alter their expression. Therefore,
we assessed the mRNA expression of key growth factors
such as nerve growth factor (NGF), brain-derived neuro-
trophic factor (BDNF), GDNF, ciliary neurotrophic fac-
tor (CNTF), and insulin-like growth factor (IGF)-1 in
astrocytes following their treatment with Th1- and
Th17-derived supernatants. Interestingly, we observed
that Th1-derived supernatants caused greater than or
equal to twofold downregulation in the expression of
NGF, BDNF, CNTF, and IGF-1 in astrocytes. In contrast,
Th17-derived supernatants did not have any influence
on the expression of these neurotrophic factors (Fig. 3).
Both Th1- and Th17-derived factors trigger a pro-
inflammatory response in astrocytes
Apart from being a key source of growth factors, astro-
cytes are important mediators of inflammation in the
CNS. Astrocytes produce not only key pro-inflammatory
cytokines such as IL-1β and IL-6 that are neurotoxic but
also some neuroprotective anti-inflammatory cytokines
such as TGF-β and IL-10. We thus studied the influence
of Th1- and Th17-derived factors on the inflammatory
response of astrocytes. We found that in response to
16 h of treatment with Th1 and Th17 supernatants, as-
trocytes significantly upregulated the mRNA expression
of pro-inflammatory genes such as IL-1β, IL-6, and nitric
oxide synthase 2 (NOS2) (greater than twofold). TNF-α
mRNA expression was enhanced by twofold in Th1-
treated astrocytes and was unchanged in Th17-treated
astrocytes (Fig. 4). On the other hand, although we ob-
served no change in TGF-β1 mRNA expression, IL-10
mRNA expression was approximately twofold lower in
Th1-treated (statistically significant) and Th17-treated
(did not yield statistical significance) astrocytes com-
pared to control medium-treated astrocytes (Fig. 4). In
our attempt to identify the factors driving activation, we
treated astrocytes with individual or a combination of
recombinant cytokines based on the knowledge we
gained from the multiplex data of Th1 and Th17 super-
natants from our previous study [13]. Similarly, we ana-
lyzed the gene expression of pro-inflammatory
chemokines and cytokines to assess astrocyte activation.
These results suggest that IFN-γ remains a potent ef-
fector of Th1 cells and combines with other effectors
Prajeeth et al. Journal of Neuroinflammation  (2017) 14:204 Page 5 of 14
such as TNF and GM-CSF to augment astrocyte activa-
tion. On the other hand, IL-17 alone had only minimal
impact and only when given in combination with TNF
to induced astrocyte activation (see Additional file 3).
Th1- and Th17-derived factors induce chemokine expres-
sion in astrocytes
In response to an inflammatory milieu, astrocytes pro-
duce several key chemokines that assist in the recruit-
ment of microglia and leukocytes from the periphery to
the sites of inflammation. Here, we assessed the influ-
ence of Th1- and Th17-derived factors on the mRNA
expression profile of chemokines in astrocytes. In gen-
eral, greater than threefold upregulation of CCL2,
CCL20, and C-X-C chemokine ligand 10 (CXCL10)
mRNA was found in astrocytes treated with Th1 and
Th17 supernatants compared to medium controls
(Fig. 5). However, mRNA expression levels of CCL2 and
CXCL10 were several folds higher in Th1-treated astro-
cytes compared to those in Th17-treated astrocytes. On
Fig. 1 Comparison of astrogliosis between wild-type and T cell-conditional α4−/− mice at the peak of EAE. Transverse lumbar spinal cord (a–d) and sagittal
brainstem (e, f) sections from wild-type and T cell-conditional α4−/− mice were stained for GFAP to assess astrocyte reactivity. Higher density of GFAP+ cells
was observed in the gray matter of the spinal cord of wild-type (a) compared to T cell-conditional α4−/− mice (b). Phenotypically distinct astrocytes were
seen at higher magnification in wild-type (c) and T cell-conditional α4−/− mice (d). Astrogliosis was comparable in the cerebellum of wild-type (e) and T
cell-conditional α4−/− mice (f). Bars = 200 μm (a, b), 50 μm (c, d), and 100 μm (e, f). Representative images for wild-type and α4−/− mice (n = 6). Intensity
GFAP fluorescence from the spinal cord (g) and cerebellum (h) was quantified using ImageJ software. The mean gray value of a selected area was
measured after subtracting the background of 8-bit grayscale image and is plotted here. Each point represents data from one mouse. Here, we used the
Mann-Whitney test for statistics; **p < 0.01
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Fig. 2 Assessment of microgliosis in wild-type and T cell-conditional α4−/− mice subjected to EAE. Immunofluorescence staining for Iba1 of
lumbar spinal cord sections reveals increased frequency of Iba+ cells in wild-type (a) compared to T cell-conditional α4−/− mice (b). Note that at
higher magnification, the microglia appeared morphologically different in wild-type (c) in comparison to T cell-conditional α4−/− mice (d). Similar
observations were made in the cerebellum of wild-type (e, g) and T cell-conditional α4−/− mice (f, h). Bars = 200 μm (a, b), 50 μm (c, d, g, h), and
100 μm (e, f). Representative images for wild-type (n = 6) and T cell-conditional α4−/− mice (n = 6). The density (cells/mm2) of Iba+ cells was
counted in the spinal cord (i) and cerebellum (j) in identical regions of wild-type and T cell-conditional α4−/− mice. Each point represents data
from one mouse. Here, we used the Mann-Whitney test for statistics; **p < 0.01
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Fig. 3 Effects of Th1- and Th17-derived factors on the expression of neurotrophic factors in astrocytes. RT-PCR analysis of RNA isolated from
astrocytes treated with medium and Th1 or Th17 supernatants for nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial
cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and insulin-like growth factor 1 (IGF-1) mRNA. Changes in mRNA
expression levels were calculated after normalization to hypoxanthine phosphoribosyltransferase (HPRT)1. The results are represented as fold
changes which were calculated by using the ΔΔCt method (i.e., normalizing the ΔCt values obtained from subjects (Th1 or Th17 treated) to those
from medium controls). The results are mean ± SEM with *p ≤ 0.05 and **p ≤ 0.01 of a minimum of four independent experiments (n = 4)
Fig. 4 Inflammatory response of astrocytes to Th1- or Th17-derived factors. mRNA expression of pro-inflammatory (IL-1β, IL-6, TNF-α, and NOS2)
and anti-inflammatory (TGF-β1 and IL-10) factors was analyzed in astrocytes exposed to medium and Th1 or Th17 supernatants. Fold change in
mRNA expression in Th1- or Th17-treated astrocytes compared to medium controls was determined. The results are mean ± SEM with *p ≤ 0.05
and **p ≤ 0.01 of a minimum of four independent experiments (n = 4)
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the other hand, CCL20 mRNA expression was more
prominently enhanced in Th17-treated astrocytes than
in Th1-treated astrocytes. CXCL12 mRNA expression
was significantly upregulated in astrocytes only in re-
sponse to Th1- and not to Th17-derived factors (Fig. 5).
In addition, enhanced expression of some of these fac-
tors (CCL2, CCL20, and IL-6) was also confirmed at the
protein level (see Additional file 4).
Enhanced migration of microglia in response to
astrocytes activated by Th1- and Th17-derived factors
Having observed that both Th1- and Th17-derived fac-
tors act on astrocytes and enhance their chemokine ex-
pression, we were interested to study if this reflects their
ability to attract microglia as it has been reported [21].
Firstly, we tested the capability of astrocytes activated by
Th1- and Th17-derived factors, respectively, to recruit
microglia using a Transwell migration assay. Astrocytes
were treated with medium and Th1- or Th17-derived
supernatants. Four hours before adding microglia to the
Transwell inserts, the stimuli were removed and the
fresh medium was added to exclude the influence of
Th1 and Th17 effectors on microglial migration. Com-
pared to medium-treated controls, we observed greater
than twofold increase in migration of microglia towards
both Th1- and Th17-treated astrocytes (Fig. 6a). Sec-
ondly, we tested if microglia recruited towards Th1- or
Th17-treated astrocytes displayed any changes in their
phagocytic ability. For this purpose, after eliminating the
Th1- and Th17-derived factors by washing, we added
microglia to Th1- and Th17-treated astrocytes. After
12 h of co-culture, uptake of latex beads by microglia as
a measure of their phagocytic ability was assessed by
flow cytometry. Interestingly, we observed an approxi-
mately threefold increase in the phagocytic ability of
microglia co-cultured with Th1-treated astrocytes,
whereas phagocytosis of microglia co-cultured with
Th17-treated astrocytes was unchanged (Fig. 6b).
Th1- and Th17-activated astrocytes enhance transen-
dothelial migration of Th17 cells
Since chemokines such as CCL20, CXCL10, and
CXCL12 are also known to play a significant role in the
chemotaxis of activated T lymphocytes, we hypothesized
that astrocytes activated by Th1- and Th17-derived fac-
tors might play a role in the recruitment of a second
wave of Th1 and Th17 cells through the BBB. To ad-
dress this, we employed a transendothelial migration
assay, where migration of Th1 and Th17 cells towards
activated astrocytes through a semi-compact endothelial
monolayer cultured on Transwell inserts was assessed.
Transwell inserts were seeded with mouse primary brain
microvascular endothelial cells (BMECs) and cultured
until they reached confluence. These inserts containing
BMEC monolayers were transferred to six-well plates
containing astrocytes that were previously treated with
medium and Th1- or Th17-derived supernatants. Fol-
lowing anti-CD3/anti-CD28 restimulation, polarized Th1
and Th17 cells were added to the Transwell inserts and
their migration towards astrocytes was measured by flow
Fig. 5 Chemokine expression profile in astrocytes exposed to medium and Th1 or Th17 supernatants. Fold changes in CCL2, CCL20, CXCL10, and
CXCL12 mRNA expression in Th1- and Th17-treated astrocytes compared to medium control were measured by RT-PCR. The results are
mean ± SEM with *p ≤ 0.05 and **p ≤ 0.01 of a minimum of four independent experiments (n = 4)
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cytometry after 12 h of incubation. Intriguingly, we
found activated Th1 cells transmigrated through the
endothelial layer with equal efficiency towards medium
and Th1- and Th17-treated astrocytes (Fig. 7a). In con-
trast, transendothelial migration of Th17 cells was poor
in response to medium-treated astrocytes and was highly
enhanced by up to threefold in response to Th1- and
Th17-treated astrocytes (Fig. 7b, c).
These results were further supported by the findings
from our EAE model where we compared the expression
of Rorc mRNA between wild-type and astrocyte-depleted
mice. Considering that Rorc expression is characteristic
to infiltrating immune cells, we used Rorc mRNA ex-
pression to assess the amount of Th17 cells in the CNS
[33]. In a previous study, we used transgenic mice
(GFAP thymidine kinase (TK)) expressing TK under the
GFAP promoter and depleted reactive astrocytes at day
7 after the onset of EAE by injecting ganciclovir (GCV).
It was found that depletion of astrocytes resulted in en-
hanced infiltration of myeloid cells and subsequent en-
hancement of disease severity [12]. Strikingly, in mice
with established EAE, astrocyte depletion showed lower
Rorc mRNA expression in the spinal cord compared to
that of non-depleted mice (see Additional file 5), hence
hinting that astrocyte activation is crucial for the recruit-
ment of Th17 cells into the CNS.
Discussion
Previously, we have demonstrated that only effector mol-
ecules released by Th1 cells had direct influence on
microglia, whereas effector molecules of Th17 cells show
no direct effects on microglia [13]. In this study, we
identified astrocytes as one of the targets of Th17 effec-
tors. We observed that during EAE, infiltration of Th17
cells alone was sufficient to induce astrogliosis in the
brain. Furthermore, we could demonstrate that factors
derived from Th1 and Th17 cells acted on astrocytes
and triggered a pro-inflammatory cytokine and chemo-
kine response that assisted the recruitment of microglia
and transendothelial migration of Th17 cells.
The current knowledge on Th1 and Th17 cells in MS
pathogenesis has come mainly from EAE models where
individual antigen-specific Th1 and Th17 cells were
adoptively transferred into the mice. However, plasticity
associated with adoptively transferred T cells is a major
limitation in understanding the contributions of specific
effectors in driving the neuroinflammation [34–36]. Mi-
gration of effector Th1 and Th17 cells into the CNS is
assisted by a distinct set of chemokine receptors and
integrins. While the integrin VLA4 (α4β1) is indispens-
able for Th1 migration, Th17 cells most likely depend
on C-C chemokine receptor 6 (CCR6) and LFA-1 [28,
37]. Earlier work has shown that interfering with specific
integrins on CD4+ T lymphocytes can modulate CNS in-
filtration of Th1 and Th17 cells [28]. Conditional knock-
out of α4 integrin in CD4 T lymphocytes (α4−/−) causes
an atypical EAE in mice with predominant infiltration of
Th17 cells and not Th1 cells into the brainstem, cerebel-
lum, and forebrain [28]. Assessment of glial reactions in
wild-type and α4−/− mice that were subjected to EAE
provided us the information of potential targets of Th17
cells in the CNS. Here, astrogliosis and microgliosis were
more pronounced in the lumbar spinal cord sections of
wild-type mice and less prominent in α4−/− mice. This
could be explained by the fact that infiltration of both
Fig. 6 Response of microglia towards Th1- or Th17-treated astrocytes.
a Migration of microglia from the upper side of the Transwell
membrane to the lower side in response to medium and Th1- or
Th17-treated astrocytes was assessed by transmigration assay
performed with microglia in the upper chamber and astrocytes plated
in the lower chamber of a Transwell system. Fold changes in transmi-
gration of microglia through the membrane in response to Th1- or
Th17-treated astrocytes compared to medium control were measured
by counting DAPI+ cells in 10 randomly selected fields on the lower
side of the membrane. The results are representative of a minimum of
five independent experiments. b The phagocytic ability of microglia
co-cultured with medium and Th1- or Th17-treated
astrocytes was measured using a latex bead uptake assay. Uptake of
fluorescently labeled beads was measured by flow cytometry. The
bar graphs represent fold change in phagocytosis of microglia
co-cultured with Th1 or Th17 supernatant-pretreated astrocytes
compared to those cultured with medium-treated astrocytes. The
results are mean ± SEM with *p ≤ 0.05 and **p ≤ 0.01 of four
independent experiments (n = 4)
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Th1 and Th17 cells into the spinal cord is drastically im-
paired in α4−/− mice [28]. In contrast, marked infiltra-
tion of Th17 cells but not Th1 cells was detected in the
cerebellum and brainstem of α4−/− mice [28]. Analyz-
ing the glial reaction of the cerebellum, we detected
comparable astrogliosis, whereas the density of micro-
glia (Iba1+) was reduced and its phenotype was strik-
ingly different in α4−/− mice despite pronounced
infiltrates of Th17 cells. These findings strongly sug-
gest that Th17 cells and their effector molecules are
capable of activating astrocytes whereas microglia are
less responsive to these cells.
We further studied if effectors of Th1 and Th17 cells
had any direct influence on astrocyte activation. Astro-
cytes are an important source of neurotrophic factors,
and downregulating their expression can trigger
neurodegeneration [38]. Here, we observed that Th1-
derived factors significantly downregulated the expres-
sion of key neurotrophic factors like NGF, BDNF, and
CNTF in astrocytes. Similarly, expression of IGF-1, a
growth factor involved in the protection of neurons
against oxidative stress, is also downregulated, suggest-
ing that effectors of Th1 cells trigger neurodegeneration
by suppressing the production of neurotrophic factor by
astrocytes. In contrast, Th17-derived factors had no in-
fluence on the expression of neurotrophic factors in
astrocytes.
Existing evidence suggests that IFN-γ and IL-17, the
key cytokines secreted by Th1 and Th17 cells, respect-
ively, are capable of regulating astrocyte function [25,
39–41]. Both Th1- and Th17-derived factors acted on
astrocytes and induced a strong pro-inflammatory
Fig. 7 Transendothelial migration of activated Th1 or Th17 cells towards Th1- or Th17-treated astrocytes. Confluent monolayers of primary mouse
brain microvascular endothelial cells (BMECs) were cultured on the upper side of Transwell inserts. These inserts were incubated for 4 h with
astrocytes that were previously treated with medium and Th1 or Th17 supernatants. Following this, activated Th1 or Th17 cells were added to
respective inserts and migration of T cells through the endothelial layer was determined by flow cytometry. a The dot plots represent the
migration of Th1 cells (upper panel) and Th17 cells (lower panel) in response to medium (right) and Th1 (middle) and Th17 (left)
supernatant-treated astrocytes. The numbers in each plot represent the FACS counts of cells in the CD4+ gate following the acquisition of the
entire sample. Fold changes in migration of Th1 (b) and Th17 (c) cells in response to Th1- or Th17-treated astrocytes were calculated by
normalizing to the migration observed in response to medium-treated astrocytes. The results are representative of at least four independent
experiments: b n = 4 and c n = 5. All data are mean ± SEM with *p ≤ 0.05 and **p ≤ 0.01
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response where expression of IL-1β, IL-6, and NOS2
mRNA was upregulated by several folds. In addition, we
observed a nearly twofold reduction in the expression of
the anti-inflammatory factor IL-10 in astrocytes treated
with Th1 and Th17 supernatants. Therefore, we believe
that effector molecules secreted by Th1 and Th17 cells
suppress an anti-inflammatory response and trigger a
potent pro-inflammatory response in astrocytes. Al-
though we have previously characterized Th1 and Th17
supernatants in terms of their cytokine profile [13], it is
not known which effector molecules were responsible
for driving astrocyte activation. It is noteworthy that
while IFN-γ remains the major effector of Th1 cells,
astrocyte activation is increased several folds when it is
combined with other factors such as TNF and GM-CSF
(see Additional file 3). IL-17 is the only major effector
detected in our Th17 supernatants along with little
amounts of TNF-α. Nevertheless, IL-17 alone had no
impact on astrocytes. Interestingly, IL-17 appears to
synergize with TNF-α, since we observed increased ex-
pression of IL-6 and CCL20 mRNA only when astro-
cytes were treated with a combination of these cytokines
(see Additional file 3). Few studies in the past have re-
ported such synergy between IL-17 and TNF-α on other
cell types [42, 43].
We also observed that Th1-derived supernatants
largely enhanced the mRNA expression of CCL2,
CXCL10, and CXCL12, whereas CCL20 expression was
highly upregulated in astrocytes treated with Th17-
derived supernatants. This is an indication that effector
molecules of Th1 and Th17 cells induce a selective che-
mokine response by astrocytes. Chemokines and their
receptors act as amplifiers of neuroinflammation by
assisting recruitment of immune cells from the periph-
ery and microglia to the inflammatory foci [44]. We have
previously shown that astrocytes are essential for recruit-
ment of microglia for myelin clearance during
cuprizone-induced demyelination and remyelination
[21]. Similarly, we observed that astrocytes treated with
Th1- or Th17-derived supernatants enhanced microglial
migration towards astrocytes. Interestingly, only micro-
glia that migrated towards Th1-treated astrocytes show
enhanced phagocytosis. Microglial phagocytosis can have
beneficial and detrimental effects in the CNS and can be
differentially regulated by several factors [45]. One such
factor, TNF-α is known to enhance the phagocytic activ-
ity of microglia [46] and we have observed that only as-
trocytes treated with Th1-derived supernatants show
enhanced expression of TNF-α.
CCL20 is constitutively expressed by the cells in the
choroid plexus and is considered to be the gateway for T
cells into the CNS [37, 47]. A few studies suggest that
CCR6, a receptor for CCL20, is expressed specifically on
Th17 and regulatory T cells and not on Th1 cells [37,
48]. Our own experience suggests that CCR6 is also
expressed on Th1 cells [49]. Nonetheless, we hypothe-
sized that Th1 and Th17 cells might activate astrocytes
and play a role in the recruitment of a second wave of
Th1 and Th17 cells. We first corroborated this hypoth-
esis using an in vitro model where we tested transen-
dothelial migration of activated Th1 and Th17 cells
towards astrocytes treated with Th1 and Th17 superna-
tants. Th1 cells crossed the endothelial barrier and were
not dependent on the activation of the astrocytes. How-
ever, increased transendothelial migration of Th17 cells
was observed only in response to astrocytes treated with
either Th1- or Th17-derived supernatants.
Previously, we and others have shown that ablation of
reactive astrocytes exacerbated clinical signs of EAE [12,
23]. In this model, we detected relatively lower expres-
sion of Rorc mRNA in the spinal cord of mice where as-
trocytes were depleted at the onset EAE, thus
supporting our above findings that astrocytes are crucial
for recruitment of Th17 cells into the CNS. Although
we observe reduced Th17 signal and more severe EAE
in the absence of reactive astrocytes, it must be remem-
bered that astrocytes are active components of the BBB
where they form the glia limitans and control the traf-
ficking of all cells through the BBB. Compromising the
BBB by depleting astrocytes leads to excess of myeloid
infiltrates into the CNS, thus triggering severe neuroin-
flammation, and this would override the effects mediated
by Th1 or Th17 cells in this model.
Conclusion
Here, we present evidence that the effectors of Th1 and
Th17 cells have distinct effects on different glial cell
types. We have previously shown that only Th1-derived
effectors influenced the phenotype and function of
microglia whereas Th17 cells had no direct effects [13].
The data from the current study show that astrocytes
are potential targets of Th17 cells in the CNS and ef-
fector molecules of both Th1 and Th17 cells had direct
influence on the phenotype and function of astrocytes.
From our data, we believe that Th1 cells act via both
microglia and astrocytes, amplify the inflammatory re-
sponse, inhibit the production of essential neurotrophic
factors, and enhance the recruitment of microglia and
Th17 cells by upregulation of essential chemokines. In
contrast, Th17 cells only act on astrocytes and impart a
pro-inflammatory phenotype to astrocytes. We believe
that this ability of Th17-derived factors to act on astro-
cytes and not on microglia might be due to the differ-
ence in the expression of receptors or signaling
molecules required for sensing Th17-derived effector
molecules. An indirect evidence for this speculation
comes from the work of Kang et al. who demonstrated
that ablation of IL-17-induced Act1 signaling on
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astrocytes ameliorates EAE, whereas ablation of this sig-
naling molecule in microglia or macrophages has no in-
fluence on the course of EAE [10]. Our results
demonstrate the delicate interaction between T cell sub-
sets and glial cells and how they communicate to medi-
ate their effects.
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Additional file 2: Clinical course of WT and α4−/− mice. EAE severity
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The basal expression was adjusted to WT-PBS controls and fold changes
in Rorc mRNA expression was determined for the other groups. Each
point represents data from one mouse. Here we used Mann-Whitney test.
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